title: Update on adjuvant hormonal treatment of early breast cancer.
abstract: Clinical trials conducted over the last two decades have demonstrated that 5 years of treatment with tamoxifen (TAM) after local treatment in postmenopausal patients with positive hormone receptor early breast cancer improves disease-free survival and overall survival. More recently, aromatase inhibitors (AI) have been tested in several randomized clinical trials in this setting. The studies have tested either AI versus TAM or different sequential approaches combining the two agents. While the most effective strategy remains to be determined, overall, incorporation of AI resulted in better disease-free survival, particularly in the worst-prognosis subgroup of patients. In addition, long-term treatment with AI was, in general, well tolerated. However, mature results are needed in order to be able to assess the effect in overall survival. The authors of this supplement paper include the key points of roundtable presentations and discussions of hormonal therapy in breast cancer by topic.
authors.affiliation: Oncology Department, Hospital Miguel Servet, Zaragoza, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Lao Romera
authors.forename: T J
authors.initials: TJ
authors.lastname: Puertolas Hernández
authors.forename: I
authors.initials: I
authors.lastname: Peláez Fernández
authors.forename: T
authors.initials: T
authors.lastname: Sampedro Gimeno
authors.forename: R
authors.initials: R
authors.lastname: Fernández Martínez
authors.forename: I
authors.initials: I
authors.lastname: Fernández Pérez
authors.forename: V
authors.initials: V
authors.lastname: Iranzo  González Cruz
authors.forename: J J
authors.initials: JJ
authors.lastname: Illarramendi Mañas
authors.forename: S
authors.initials: S
authors.lastname: Garcerá Juan
authors.forename: E M
authors.initials: EM
authors.lastname: Ciruelos Gil
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000077384:Anastrozole; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D047072:Aromatase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D009367:Neoplasm Staging; D009570:Nitriles / Q000008:administration & dosage / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole